Humana Inc.
Humana Inc. Q2 FY26 Results — Earnings Call Analysis
Q2 FY26 earnings call: what management said on revenue, margins and capex.
What the Q2 FY26 call signalled
2 of 4 strong
The short version
- Membership growth trajectory is on track, with dynamic management of distribution and growth if needed (Page 2). - Humana expects to double individual Medicare Advantage (MA) margins in 2026, adjusted for Stars performance.
From Humana Inc.'s Q2 FY26 earnings-call transcript · updated 29 May 2026.
Revenue & Sales Performance
- Membership growth trajectory is on track, with dynamic management of distribution and growth if needed (Page 2).
- Solid growth across CenterWell's lines of business: pharmacy, primary care (including recent Max Health acquisition), and home health (Page 6).
- Expansion of CenterWell’s reach into new critical markets through acquisitions like Max Health (Page 2, 6).
- Continued Medicaid membership growth (~50,000 lives) from new program starts in Michigan, Illinois, and South Carolina (Page 2).
- Anticipated doubling of individual Medicare Advantage (MA) margin in 2026, reflecting improved operational performance and pricing discipline (Page 2).
- Stable and compelling MA margin expected, unlocking earnings potential by 2028 (Page 3).
2 more points from Humana Inc.'s call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Humana Inc. said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Humana is pursuing noncore asset divestitures to help fund strategic acquisitions and expects to share more news on this in the coming months. (Page 3)
- They have executed initiatives to optimize the balance sheet, including subsidiary reinsurance and legal entity restructuring, mitigating over $3 billion in capital contribution requirements for 2026. (Page 3)
- Issued $1 billion junior subordinated notes in March, expected to fund 2027 maturities, indicating capital management and funding for future investments. (Page 3)
- Continuing to evaluate a pipeline of initiatives to further strengthen the balance sheet, supporting ongoing and future strategic investments. (Page 3)
Fundraising & Capital Structure
See what Humana Inc. said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
2 more points from Humana Inc.'s call on order book
Create a free account to keep reading this call
Continue your research
Others in Health Care Providers and Services this season
- BrightSpring Health Services, Inc. (Q2 FY26)
BrightSpring Health Services, Inc. Q2 FY26 quarterly results analysis. Pharmacy Solutions expected to see balanced sequential revenue and EBITDA growth througho
- DaVita Inc. (Q2 FY26)
DaVita Inc. Q2 FY26 quarterly results analysis. Treatment volume guidance raised from flat to 25-50 basis points growth for 2026, driven by better underlying pe
- Tenet Healthcare Corporation (Q2 FY26)
Tenet Healthcare Corporation Q2 FY26 quarterly results analysis. Hospital segment expects a 10% normalized year-over-year adjusted EBITDA growth in 2026, suppor
- Guardant Health, Inc. (Q2 FY26)
Guardant Health, Inc. Q2 FY26 quarterly results analysis. Sales team started this year with ~300 reps; incremental gross profit will be reinvested in expanding
Potential multibaggers · Q2 FY27
This quarter's potential multibaggers
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Humana Inc. and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Humana Inc. Q2 FY26 results?
- Membership growth trajectory is on track, with dynamic management of distribution and growth if needed (Page 2). - Humana expects to double individual Medicare Advantage (MA) margins in 2026, adjusted for Stars performance.
What is Humana Inc. share price analysis?
Humana Inc. currently shows a below-average growth signal. The stock trades at a P/E of 32.2 with a market cap of $37,063. Investors should review the full earnings analysis for detailed insights.
Is Humana Inc. planning capital expenditure?
- Humana is pursuing noncore asset divestitures to help fund strategic acquisitions and expects to share more news on this in the coming months.
Keep Humana Inc. on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.